REIGN PHARMA PVT LTD
Balance Sheet as at 31st March, 2024
SHOP NO 402 4 TH FLOOR
JUNGADH
JUNGADH-362001
CIN : U24290GJ2019PTC108167

(Rs.in Hundred)

	Particulars	Note No.	As at 31 March, 2024		As at 31 March, 2023	
				(Rs.)		(Rs.)
A	**EQUITY AND LIABILITIES**					
1	**Shareholders' Funds**					
	(a) Share Capital	2	49,000.00		49,000.00	
	(b) Reserves and Surplus	3	-1,43,986.02	-94,986.02	-1,02,081.11	-53,081.11
2	**Non-current Liabilities**					
	(a) Other Long-term Liabilities	4	5,51,614.67		6,12,634.57	
	(b) Long-term Provisions	5	-	5,51,614.67	-	6,12,634.57
3	**Current Liabilities**					
	(a) Trade Payables	6				
	-Total Outstanding Dues of Micro Enterprises and Small Enterprises		-		-	
	-Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		1,84,318.20		73,588.10	
	(b) Other Current Liabilities	7	-		-	
	(c) Short-term Provisions	8	-	1,84,318.20	-	73,588.10
	TOTAL			**6,40,946.85**		**6,33,141.56**
B	**ASSETS**					
1	**Non-current Assets**					
	(a) Property Plant and Equipment	9				
	(i) Tangible Assets	9(a)	4,82,066.95		5,16,734.90	
	(ii) Intangible Assets	9(b)	-		-	
	(b) Non-Current Investments	10	-		-	
	(c) Long-term Loans and Advances	11	-		-	
	(d) Other Non-Current Assets	12	-	4,82,066.95	-	5,16,734.90
2	**Current Assets**					
	(a) Inventories					
	Finished Goods		20,520.00		-	
	Raw Material					
	(a) Trade Receivables	13	26,168.70		5,523.99	
	(b) Cash and Cash Equivalents	14	28,609.95		17,079.68	
	(c) Short-term Loans and Advances	15	83,581.25		93,802.99	
	(d) Other Current Assets	16	-	1,58,879.90	-	1,16,406.66
	TOTAL			**6,40,946.85**		**6,33,141.56**
	Summary of Significant Accounting Policies	1				

The accompanying notes form an integral part of the Financial Statements

In terms of our report attached.
For D.T.SAMANI & CO.
Chartered Accountants
Firm Regn. No. - 038787

For and on behalf of the Board of Directors of
REIGN PHARMA PRIVIATE LIMITED.

D.T. SAMANI & Co. SF-24 Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787 Chartered Accountants

DAMODAR SAMANI
Proprietor
Membership No. 038787

DIRECTOR
DIN: 08443629
KISHAN VAGHASIYA

DIRECTOR
DIN: 08443637
DHIRAJLAL NARIYA

UDIN : 24038787BKCJNF4282
Place : ANKLESHWAR
Date : 28/08/2024

Place : Ankleshwar
Date : 28/08/2024

REIGN PHARMA PVT LTD
Statement of Profit and Loss for the year ended 31 March, 2024
SHOP NO 402 4 TH FLOOR
JUNGADH
JUNGADH-362001
CIN : U24290GJ2019PTC108167

(Rs.In Hundred)

	Particulars	Note No.	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
A	CONTINUING OPERATIONS			
1	Revenue from Operations	17	1,87,548.21	18,652.00
2	Other Income	18	232.88	0.00
3	Total Income (1+2)		1,87,781.09	18,652.00
4	Expenses			
	(a) Cost of Material Consumed	19	1,19,926.47	13,331.77
	(b) Employee Benefit Expense	20	6,702.14	4,420.00
	(c) Finance Costs	21	31,148.26	26,880.46
	(d) Depreciation and Amortisation Expense	9	57,006.13	61,139.08
	(e) Other Expenses	22	14,903.00	9,252.44
	(e) Prior period Items (Net)	23	-	
	Total Expenses		2,29,686.00	1,15,023.75
5	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (3 - 4)		-41,904.91	-96,371.75
6	Exceptional Items		-	-
7	Profit/(Loss) before Extraordinary Items and Tax (5 - 6)		-41,904.91	-96,371.75
8	Extraordinary items		-	-
9	Profit/(Loss) before tax (7 - 8)		-41,904.91	-96,371.75
10	Tax expense:			
	(a) Current tax expense for current year		-	-
	(b) Deferred tax		-	-
	Net current tax expense		-	-
11	Profit/(Loss) from Continuing Operations (9 - 10)		-41,904.91	-96,371.75
12	Profit/(Loss) for the Year		-41,904.91	-96,371.75
13.i	Earnings/(Loss) per Equity Share (of Rs.10/- each):	24		
	(a) Basic		-419.05	-963.72
	(b) Diluted		-419.05	-963.72
	Summary of Significant Accounting Policies	1		
	The accompanying notes form an integral part of the Financial Statements			

In terms of our report attached.
For D.T.SAMANI & CO.
Chartered Accountants
Firm Regn. No. - 038787

D.T. SAMANI & CO. SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787 Chartered Accountants

DAMODAR SAMANI
Proprietor
Membership No. 038787

UDIN : 24038787BKCJNF4282
Place : ANKLESHWAR
Date : 28/08/2024

For and on behalf of the Board of Directors of
REIGN PHARMA PRIVIATE LIMITED.

DIRECTOR
DIN: 08443629
KISHAN VAGHASIYA

DIRECTOR
DIN: 08443637
DHIRAJLAL NARIYA

Place : ANKLESHWAR
Date : 28/08/2024

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements

Note 2 Share Capital

(Rs.In Hundred)

Particulars	As at 31 March, 2024		As at 31 March, 2023	
	Number of shares	Rs.	Number of shares	Rs.
(a) Authorised				
Equity shares of Rs.10/- each with voting rights	**8,00,000**	**80,000**	8,00,000	80,000
		80,000		**80,000**
(b) Issued				
Equity shares of Rs. 10/- each with voting rights	**4,90,000**	**49,000**	4,90,000	49,000
		49,000		**49,000**
(c) Subscribed and fully paid up				
Equity shares of Rs. 10/- each with voting rights	**4,90,000**	**49,000**	4,90,000	49,000
	4,90,000	**49,000**	**4,90,000**	**49,000**

Footnotes:

2.1 The company has one class of equity shares having a par value of Rs.10/- per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholding.

2.2 Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	As at 31 March, 2024		As at 31 March, 2023	
	Number of shares	Rs.	Number of shares	Rs.
Equity Shares with voting rights				
As at the beginning of the year	**4,90,000**	**49,000**	4,90,000	49,000
As at the end of the year	**4,90,000**	**49,000**	4,90,000	49,000

2.3 Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March, 2024		As at 31 March, 2023	
	Number of shares held	% holding	Number of shares held	% holding
Equity shares with voting rights				
DHIRAJ NARIYA	1,27,400	26.00	1,27,400	26.00
GIRDHAR VANPARIYA	24,500	5.00	24,500	5.00
KISHAN VAGHASIYA	1,12,700	23.00	1,12,700	23.00
NITABEN VAGHASIYA	98,000	20.00	98,000	20.00
RAMESH NARIYA	1,27,400	26.00	1,27,400	26.00
		-	-	-
	4,90,000	100.00	4,90,000	100.00

2.4 No Dividend is proposed by the Board of Directors for the Current Financial Year. (Previous Year- Nil)

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co.
SF-24
Ravikiran Complex,
Valiya Road, G.I.D.C.,
Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements

Note 3 Reserves and Surplus

(Rs.In Hundred)

Particulars		As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
(a) Capital redemption reserve			
Opening balance		0.00	0.00
Closing Balance	**Total(A)**	**0.00**	**0.00**
(b) General reserve			
Opening balance		0.00	0.00
Closing Balance	**Total(B)**	**0.00**	**0.00**
(c) Surplus in Statement of Profit and Loss			
Opening balance		-1,02,081.11	-5,709.36
Add: Profit for the year		-41,904.91	-96,371.75
Transferred to:			
Closing Balance	**Total(C)**	**-1,43,986.02**	**-1,02,081.11**
	Total (D = A+B+C)	**-1,43,986.02**	**-1,02,081.11**

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002
M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD

Notes forming part of the Financial Statements

Note 4 Other Long-Term Liabilities

(Rs.In Hundred)

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
Term Loan	5,51,614.67	6,12,634.57
Loans & Advance from Related Parties		-
Total	**5,51,614.67**	**6,12,634.57**

Note 5 Long-Term Provisions

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
Provision for Employee Benefits:		
(i) Provision for Gratuity	-	-
(ii) Provision for Leave Encashment	-	-
Total	-	-

Note 6 Trade Payables

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
Total Outstanding Dues of Micro Enterprises and Small Enterprises (Refer Note No.30)	-	-
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	1,84,318.20	73,588.10
Total	**1,84,318.20**	**73,588.10**

Note 7 Other Current Liabilities

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
Unpaid Dividends*	-	-
Statutory Dues (GST)	-	-
Advance from Customers	-	-
Staff Related Dues	-	-
Other Payables	-	-
Total	-	-

***There are no amounts due & outstanding to be credited to Investor Education & Protection Fund.**

Note 8 Short-Term Provisions

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
(a) Provision for employee benefits:		
(i) Provision for Gratuity	-	-
(ii) Provision for Leave Encashment		
(iii) TDS Payable	-	-
Total A	-	-

D. T. SAMANI & CO.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

REIGN PHARMA PVT LTD

Notes forming part of the Financial Statements

Note 9 Property Plant and Equipment

Note 9(a) TANGIBLE ASSETS **(Rs.In Hundred)**

Particulars	Building	Furniture & Fixture	Machinery	Total
Gross Block				
As at April 1, 2020	-	-	-	-
Additions	-	-	-	-
Deductions	-	-	-	-
As at March 31, 2021	1,59,045.01	-	1,21,436.35	2,80,481.36
Additions	-	-	-	-
Deductions	-	-	-	-
As at March 31, 2022	1,59,045.01	-	1,21,436.35	2,80,481.36
Additions	47,727.28	4,924.45	2,44,740.89	
Deductions	-	-	-	
As at March 31, 2023	2,06,772.29	4,924.45	3,66,177.24	5,77,873.98
Additions	2,000.00		20,338.18	
Deductions				
As at March 31, 2024	2,08,772.29	4,924.45	3,86,515.42	5,77,873.98
Depreciation				
As at April 1, 2020	-	-	-	-
Charge for the year	-	-	-	-
Deductions	-	-	-	-
As at March 31, 2021	-	-	-	-
Charge for the year	-	-	-	-
Deductions	-	-	-	-
As at March 31, 2022	-	-	-	-
Charge for the year	7,606.30	464.97	53,067.81	61,139.08
Deductions				
As at March 31, 2023	7,606.30	464.97	53,067.81	61,139.08
Charge for the year	7,295.67	668.92	49,041.54	57,006.13
Deductions				
As at March 31, 2024	14,901.97	1,133.89	1,02,109.35	1,18,145.21
Net Block				
As at March 31, 2021	1,59,045.01	-	1,21,436.35	2,80,481.36
As at March 31, 2022	1,59,045.01	-	1,21,436.35	2,80,481.36
As at March 31, 2023	1,99,165.99	4,459.48	3,13,109.43	5,16,734.90
As at March 31, 2024	1,93,870.32	3,790.56	2,84,406.07	4,82,066.95

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co. Chartered Accountants SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements
Note 10 Non- Current Investments

(Rs.In Hundred)

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
NON- CURRENT INVESTMENTS		
(Long Term, other than trade, fully paid up, at cost)		
A UNITS OF MUTUAL FUNDS (Unquoted)		
1 15398.184 Units (PY 15398.184 Units) HDFC Balance Advantage Fund- Regular Plan-D	-	-
B OTHER INVESTMENT (Unquoted)	-	-
1 1,000,000 Units (PY 1,000,000 Units) IIFL Real Estate Fund	-	-
	-	-
	-	-
Less: Provision for Dimunition in Value of Investments in IIFL Real Estate Fund	-	-
	-	-
Aggregate Value of Unquoted Investment	-	-
Aggregate Dimunition in the Value of Investment	-	-

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements

Note 11 Long-Term Loans and Advances

(Rs.In Hundred)

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
(a) Security deposits		
Unsecured, Considered Good	-	-
(b) Advance Payment of Tax	-	-
(Net of provision of tax Rs. Nil, previous year Rs. Nil)		
Total	-	-
(f) Other loans and advances		
Unsecured Considered Good	-	-
Unsecured, Considered Doubtful	-	-
Less: Provision for other doubtful loans and advances	-	-
	-	-
Total	-	-

Note 12 Other Non-current Assets

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
(a) Accruals		
(b) Others	-	-
Total	-	-

Note 13 Trade Receivables

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
Trade receivables		
Outstanding for a period exceeding six months from the date they become due for payment		
Unsecured, considered good	-	-
Unsecured Considered Doubtful	-	-
Provision for doubtful receivables	-	-
	-	-
Others		
Unsecured, considered good	26,168.70	5,523.99
Total	26,168.70	5,523.99

Note 14 Cash and Bank Balances

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
(a) Cash & Cash Equivalent		
Cash on hand	12,234.28	10,065.21
Balances with banks:	16,375.67	7,014.47
Total Cash & Cash Equivalent	28,609.95	17,079.68
(b)Other balances with banks		
In Fixed Deposits with original maturity of more than 3 months	-	-
In Unpaid Dividend Account	-	-
Total Cash & Bank Balances	28,609.95	17,079.68

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co. Chartered Accountants SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787

REIGN PHARMA PVT LTD

Notes forming part of the Financial Statements

Less: In Fixed Deposits with maturity of more than 12 months classified as non current (Refer note no.12)	-	-
	28,609.95	17,079.68

Note 15 Short-Term Loans and Advances (Unsecured, Considered Good)

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
(a) Prepaid Expenses	-	-
(b) Other Loans & Advances	14,440.83	19,345.91
(c) Deposit	5,467.00	5,257.41
(d)Balances with Government Authorities	63,673.41	69,199.67
Total	83,581.24	93,802.99

Note 16 Other Current Assets

Particulars	As at 31 March, 2024 (Rs.)	As at 31 March, 2023 (Rs.)
Accrual		
(i) Interest Accrued on fixed deposits	-	-
(ii) Other Amount Recoverable	-	-
Total	-	-

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & CO.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements

Note 17 Revenue from Operations

(Rs.In Hundred)

	Particulars	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
(a)	Sale of Products	1,87,548	18,652
(b)	Sale of Services	-	-
	Total	1,87,548.21	18,652.00

Note 18 Other Income

	Particulars	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
(a)	Interest Income	232.88	-
(b)	Income from Real Estate Investment Fund	-	-
(c)	Dividend income:	-	-
	Long-Term Investments	-	-
(e)	Profit on sale of fixed assets	-	-
(d)	Liabilities written back	-	-
(e)	Provisions for doubtful debt written back	-	-
(f)	Excess Provision for Leave Enchashment written off	-	-
(g)	Profit on Sale of Fixed Assets	-	-
(h)	Miscellaneous income	-	-
(f)	Profit on Sale of Fixed Assets	-	-
	Total	232.88	-

	Particulars	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
18(i)	Interest income comprises:		
	Interest from banks on Deposits	-	-
	Interest on Income Tax Refund	-	-
	Total - Interest income	-	-

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & CO.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD
Notes forming part of the financial statements

Note 19 Cost of Material Consumed

(Rs.In Hundred)

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023
	(Rs.)	(Rs.)
Opening Stock	-	-
Add: Purchase	1,40,446.47	13,331.77
Less: Closing Stock	20,520.00	-
Total	1,19,926.47	13,331.77

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co.
SF-24, Ravikiran Complex,
Valiya Road, G.I.D.C.,
Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements

Note 20 Employee Benefits Expense

(Rs.In Hundred)

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023
	(Rs.)	(Rs.)
Salaries and wages	6,702.14	4,420.00
Bonus	-	-
Whole Time Director's Remuneration	-	-
Contributions to provident and other funds (Refer Note no.28(b))	-	-
Staff welfare expenses	-	-
Gratuity Expense (Refer Note No.31)	-	-
Leave Encashment	-	-
Total	6,702.14	4,420.00

Note 21 Finance Costs

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023
	(Rs.)	(Rs.)
Interest expense on:		
(i) Others		
- Interest on Loan	30,858.98	26,880.46
- Others	-	-
Bank Charges	289.28	-
TDS	-	-
Total	31,148.26	26,880.46

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

REIGN PHARMA PVT LTD
Notes forming part of the Financial Statements

Note 22 Other Expenses

(Rs.In Hundred)

Particulars	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
Electricity Exp	9,042.33	4,584.02
Water Exp	1,066.26	777.32
Accounting Writing Charges	180.00	150.00
Dranage Exp	74.17	46.70
Insurance Exp	1,709.89	1,363.08
Office Expense	152.02	102.88
Professional Charges	691.18	914.00
Rebate & Discount	-13.36	0.11
Repairing & Maintance Exp	462.64	325.77
Security Service	-	120.00
Telephone Exp	135.42	-
Transport Exp	258.74	-
Travelling Expense	1,023.71	664.01
Bank Charges	-	54.55
Payments to the auditors comprises (Refer 22 (i)	120.00	150.00
Total	14,903.00	9,252.44

Particulars	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
22(i) Payments to the auditors comprises :		
As Auditors	-	-
For Taxation matters	-	-
For other services	120.00	150.00
Total	120.00	150.00

Note 23 Prior Period Item(Net)

Particulars	For the year ended 31 March, 2024 (Rs.)	For the year ended 31 March, 2023 (Rs.)
Electricity Expenses Reversed as Security Deposit	-	-
Digital Expenses	-	-
	-	-

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & CO. Chartered Accountants SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002, M. No. 38787

NOTES TO FINANCIAL STATEMENTS
for the year ended 31st March 2024

Note: 1 SIGNIFICANT ACCOUNTING POLICIES AND PRACTICES

Basis Of Preparation Of Financial Statements

The accounts have been prepared on the basis of historical cost convention on the accrual concept of accounting in accordance with generally accepted accounting principle in India and are in compliance with the accounting standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 2013.

Revenue Recognition

Company follows mercantile system of accounting and recognizes significant items of income on accrual basis.

1. Revenue from Sale of goods is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer.
2. Income from the services are recognised as and when the services are rendered.
3. Interest income is recognized on the time proportion method taking into account the amount outstanding and the applicable rate of interest.

Use of Estimates

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known / materialized.

Employees Benefits

Expenses and liabilities in respect of employee benefits are recorded in accordance with Accounting Standard -

15 Employee Benefits (Revised 2005) "Revised AS 15".
Contribution to provident fund and Pension fund scheme are paid in accordance with applicable statutes and

deposited with the Regional Provident Fund Commissioner
The company has defined benefit plans namely Gratuity for the employees, the liability for which is determined

on the basis of an actuarial valuation at the year end by an independent actuary, liability/ Assest, if any, is provided for in the books.
Actuarial Gains and Losses comprise of experience adjustments and the effects of changes in actuarial assumptions and are recognized immediately in the Profit and Loss Account as income or expense.

Inventories

1. Raw Materials, Packing Materials, Stocks of stores and spares are valued at lower of cost or net realizable value for this purpose, cost is determined on FIFO basis. However, the aforesaid items are not valued below cost if the finished products in which they are to be incorporated are expected to be sold at or above cost.

2. Semi-finished products, finished products and by products are valued at lower of cost or net realizable value and for this purpose, cost is determined on standard cost basis which approximates the actual cost. Cost of finished goods excludes applicable excise duty.
3. Traded goods are valued at lower of Cost and Net Realizable Value.
4. Stock of Waste if any is accounted at realisable value
5. Figures reflected in inventories include declared stock under Income Tax survey.

D. T. SAMANI & CO. SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787 Chartered Accountants

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

Sundry Debtors and Loans and Advances

Sundry debtors and Loans and Advances are stated after making adequate provisions for doubtful balances.

Fixed Assets

Fixed Assets are stated at cost of acquisition/construction less accumulated depreciation and impairment losses, if any. Cost includes taxes, duties, freight and other incidental expenses related to acquisition / construction. Interest on borrowings, to finance acquisition of fixed assets during construction period is capitalized. Renewals and replacements are either capitalized or charged to revenue as appropriate, depending upon the nature of long-term utility of such renewals and/or replacement.

Depreciation and Amortization

Depreciation is provided on written down value basis u/s 123 of the Companies Act 2013, at the rates prescribed in the Schedule II of the said Act and as per best estimates by management of company in respect of Fixed Assets lying and situated mainly at "Ankleshwar Factory" and "Ahmedabad Office" units of the Co.

Depreciation on assets added / disposed-off during the year has been provided on pro-rata basis with reference to the month of addition/disposal.

Impairment of Assets

At each balance sheet date, the Company reviews the carrying amounts of its fixed assets to determine whether there is any indication that those assets suffered impairment loss. If any such indication exists, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash-generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the profit and loss account. If at the balance sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciated historical cost.

Investments

Investments intended to be held for more than a year are classified as non current investment and all other investments are classified as current investments. Non Current investments are stated at cost or market value whichever is less. The cost of Investment/Stock of Trade Securities includes brokerage and other expenses, if any.

Current investments if any are stated at lower of cost and fair value on an individual investment basis.

A provision for diminution is made to recognize a decline, other than temporary, in the value of investments.

Foreign Currency Transactions

Foreign currency transactions during the period are recorded at the exchange rate prevailing on the date of transaction. Balances in form of current assets and current liabilities in foreign currency if any, outstanding at the close of the year, are converted in Indian currency at rates prevailing on the date of balance sheet.

Foreign currency assets and liabilities covered by forward contracts/derivatives are stated at the contracted rate, while those not covered by the contracts are restated at rates prevailing at the balance sheet date.

All exchange differences are dealt with in the profit and loss account.

Accounting for Derivatives

D. T. SAMANT & Co. SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787 Chartered Accountants

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

The Company uses derivatives instruments to hedge its exposure to movements in foreign exchange rates. The objective of these derivative instruments is only to reduce the risk or cost to the company and is not intended for trading or speculation purposes.

Taxes On Income

Appropriation of current year tax is provided

Deferred tax resulting from "timing differences" between accounting and taxable profit for the period is accounted for using the tax rates and laws that have been enacted or substantively enacted as at the balance sheet date.

Deferred tax assets is recognized and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such assets can be realized.

Provisions, Contingent Liabilities And Contingent Assets

Provision is recognized when an enterprise has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation and in respect of which a reliable estimate can be made. Provisions are determined based on management estimates required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimate.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, requires an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are neither recognized nor disclosed.

Provisions, Contingent Liabilities and Contingent Assets are reviewed at each balance sheet date.

Borrowing Costs

Interest and other borrowing costs attributable to qualifying assets are capitalized. Other interest and borrowing costs are charged to revenue. Interest on Directors' loan is not provided during FY 2023-24

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director

D. T. SAMANI & Co.
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002.
M. No. 38787
Chartered Accountants

		2023-24			Variance
		Numerator	Denominator	Ratio	
Current Ratio,	Current Assets/Current Liabilities	158879.9	184318.2	0.86	
Debt-Equity Ratio,	NA				
Debt Service Coverage Ratio,	NA				
Return on Equity Ratio,	Net Income/Average Shareholder's Equity	-41,904.91	49000	-0.86	
Inventory turnover ratio,	NA				
Trade Receivables turnover ratio,	Net Credit Turnover/Average Trade Receivables	1,87,548.21	15846.345	11.84	
Trade payables turnover ratio,	Net Purchases/Average Trade Payables	-	128953.15	0.00	
Net capital turnover ratio,	Sales/Net Assets	1,87,548.21	456628.65	0.41	
Net profit ratio,	Net Profit/Revenue from Operations	-41,904.91	1,87,548.21	-0.22	
Return on Capital employed,	Net Profit before Interest and Tax/Capital Employed	#REF!	456628.65	#REF!	
Return on Fixed Deposits	Interest Income on Deposits with Bank/Average Fixed Deposit	#REF!	0	#REF!	
Return on Other Investments	Net Gain on Other Investments/ Average Investments	#REF!	0	#REF!	

		2022-23		
		Numerator	Denominator	Ratio
Current Ratio,	Current Assets/Current Liabilities	116406.66	73588.1	1.58
Debt-Equity Ratio,	NA			
Debt Service Coverage Ratio,	NA			
Return on Equity Ratio,	Net Income/Average Shareholder's Equity	-96,371.75	49000	-1.97
Inventory turnover ratio,	NA			
Trade Receivables turnover ratio,	Net Credit Turnover/Average Trade Receivables	18,652.00	3031.98	6.15
Trade payables turnover ratio,	Net Purchases/Average Trade Payables	-	197.99	0.00
Net capital turnover ratio,	Sales/Net Assets	18,652.00	559553.46	0.03
Net profit ratio,	Net Profit/Revenue from Operations	-96,371.75	18,652.00	-5.17
Return on Capital employed,	Net Profit before Interest and Tax/Capital Employed	#REF!	559553.46	#REF!
Return on Fixed Deposits	Interest Income on Deposits with Bank/Average Fixed Deposit	#REF!	139175	#REF!
Return on Other Investments	Net Gain on Other Investments/ Average Investments	#REF!	93836.215	#REF!

Terms

Net Profit before Interest and Tax	Net Profit-Interest on Non-Trade Investments+Expense on Non-Trade Investments+Interest on Long-Term Borrowings
Capital Employed	Share Capital+Reserves and Surplus+Non-Current Liabilities-Non-Trade Investments
Net Assets	Net Fixed Assets+Long Term Assets+Net Current Assets
	Net Current Assets=Current Assets-Current Liabilities

D. T. SAMANI & Co. Chartered Accountants
SF-24, Ravikiran Complex, Valiya Road, G.I.D.C., Ankleshwar-393 002. M. No. 38787

For, Reign Pharma Pvt. Ltd.

Director

For, Reign Pharma Pvt. Ltd.

Director